C07K 14/115
Paramyxoviridae
Official title: Paramyxoviridae, e.g. parainfluenza virus
C07K14/115 (Paramyxoviridae) appears on 46 US grants and 100 published applications in this corpus.
Search patents in C07K- Granted patents
- 46
- Published applications
- 100
- Assignees
- 66
- Inventors
- 194
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 1 | 0 |
| 2012 | 0 | 2 |
| 2013 | 0 | 7 |
| 2014 | 3 | 2 |
| 2015 | 3 | 6 |
| 2016 | 2 | 5 |
| 2017 | 1 | 3 |
| 2018 | 2 | 5 |
| 2019 | 3 | 9 |
| 2020 | 1 | 5 |
| 2021 | 8 | 11 |
| 2022 | 6 | 7 |
| 2023 | 4 | 9 |
| 2024 | 3 | 12 |
| 2025 | 7 | 5 |
| 2026 | 2 | 10 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Mumps and measles virus immunogens and their use26 May 2026US 12,636,360 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Human hendra virus and nipah virus antibodies and methods of use therefor24 Feb 2026US 12,559,545 B2Vanderbilt University
- Compositions and methods for stimulating natural killer cells7 Oct 2025US 12,435,121 B2University of Central Florida Research Foundation, Inc.
- Recombinant vaccine against Marek's disease and Newcastle disease25 Mar 2025US 12,258,372 B2The United States of America as represented by the Secretary of Agriculture
- Recombinant metapneumovirus f proteins and their use25 Feb 2025US 12,233,124 B2Institute for Research in Biomedicine
- Mumps and measles virus immunogens and their use20 Aug 2026US 2026/0240984 A1The United States of America, as represented by the Secretary, Department of Health and Human Ser.
- Engineered protein g fusogens and related lipid particles and methods thereof13 Aug 2026US 2026/0234669 A1Sana Biotechnology, Inc.
- Engineered paramyxovirus soluble fusion (f) proteins and related vaccines30 Jul 2026US 2026/0217772 A1The Scripps Research Institute
- Recombinant rsv vaccine: methods of making and using the same9 Jul 2026US 2026/0193671 A1Blue Lake Biotechnology, Inc.
- Pre-fusion human piv1 f proteins21 May 2026US 2026/0139011 A1Janssen Vaccines & Prevention B. V.
Most cited
By later US patents
- Henipavirus vaccine9US 11,524,066 B2CureVac AG · 2022
- Stabilized soluble pre-fusion RSV F polypeptides7US 10,899,800 B2Janssen Vaccines & Prevention B. V. · 2021
- Stabilized pre-fusion RSV F proteins5US 10,953,087 B2Janssen Vaccines & Prevention B. V. · 2021
- Pepmixes to generate multiviral CTLs with broad specificity5US 11,118,164 B2Baylor College of Medicine · 2021
- Stabilized soluble pre-fusion RSV F proteins5US 11,155,583 B2Janssen Vaccines & Prevention B. V. · 2021